Gossamer Bio Announces Publication of Key Preclinical Data in the European Respiratory Journal Highlighting Seralutinib's Potential for the Treatment of PAHBusiness Wire • 06/09/22
Wall Street Analysts Believe Gossamer Bio (GOSS) Could Rally 113%: Here's is How to TradeZacks Investment Research • 05/26/22
Gossamer Bio (GOSS) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Zacks Investment Research • 05/23/22
Gossamer Bio Announces First Quarter 2022 Financial Results and Provides Business UpdateBusiness Wire • 05/10/22
Gossamer Bio Announces GB004 Topline Results from Phase 2 SHIFT-UC Study in Ulcerative Colitis and Provides Corporate UpdateBusiness Wire • 04/25/22
Gossamer Bio Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Business UpdateBusiness Wire • 03/03/22
Gossamer Bio to Announce Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 3, 2022Business Wire • 02/28/22
Gossamer Bio, Inc. (GOSS) CEO Faheem Hasnain on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/09/21
Gossamer Bio Announces Third Quarter 2021 Financial Results and Provides Corporate UpdateBusiness Wire • 11/08/21
Gossamer Bio to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021Business Wire • 11/02/21
Gossamer Bio Announces Addition of Two CNS-Penetrant BTK Inhibitors to its Product Candidate Pipeline: GB5121 & GB7208Business Wire • 10/11/21
Gossamer Bio to Host Webcast Announcing its Next Clinical Product Candidates on October 11, 2021Business Wire • 10/07/21
Gossamer Bio Announces Appointment of Bryan Giraudo as Chief Operating Officer, in addition to Chief Financial Officer RoleBusiness Wire • 09/21/21
Gossamer Bio, Inc. (GOSS) CEO Faheem Hasnain on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/10/21
Gossamer Bio Announces Second Quarter 2021 Financial Results and Provides Corporate UpdateBusiness Wire • 08/09/21
Gossamer Bio to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 9, 2021Business Wire • 08/02/21
Gossamer Bio Announces GB004 Clinical Trial Data Presentations at 2021 Virtual Congress of the European Crohn's and Colitis OrganisationBusiness Wire • 07/07/21
Gossamer Bio Announces Promotion of Richard Aranda, M.D., to Chief Medical OfficerBusiness Wire • 06/21/21
Gossamer Bio Announces Appointment of Sandra Milligan, M.D., J.D., to its Board of DirectorsBusiness Wire • 06/14/21
Gossamer Bio Announces First Quarter 2021 Financial Results and Provides Corporate UpdateBusiness Wire • 05/06/21
Gossamer Bio Announces Executive Management Transition and Promotion of Laura Carter, Ph.D., to Chief Scientific OfficerBusiness Wire • 04/20/21
Gossamer Bio Announces Promotion of Caryn Peterson to Executive Vice President, Regulatory AffairsBusiness Wire • 04/16/21
Gossamer Bio, Inc. (GOSS) CEO Faheem Hasnain on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/27/21
Gossamer Bio Announces Fourth Quarter and Full-Year 2020 Financial Results and Provides Business UpdateBusiness Wire • 02/25/21